Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Net Income

Bottom-line profit after all expenses, interest, and taxes.

Genmab A/SNASDAQ: GMAB

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of $303M fell 9.8% year over year. Sequentially, it rose 469.6% from the prior quarter. Over 3 fiscal years it compounded at -43.9% a year.

Context

  • Net income amounted to 25.9% of revenue in FY2025, down 10.6 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 15 analysts of $774.08M (-19.7%) for the fiscal year ending Dec 2026, a step up from the -87.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$303M+469.6% QoQ
Last fiscal yearDec 2025
$963.76M-87.7% YoY
LTMJun 2026
$788.1M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.8%-40.7%-30.9 pp
1 year-87.7%-19.7%+68.0 pp
3-year CAGR-43.9%+18.6%+62.5 pp
5-year CAGR+11.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the income statement

Latest · FY2025
963.76M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Net income amounts to 19.1% of revenue for GMAB, versus a peer median of 48.0%.
GMAB Competitors
Net Income for GMAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.61B USD+85.1%+55.7%27.7%
EXELExelixis, Inc.LTM Jul 2026$860.62M USD+42.9%+62.5%35.3%
GMABGenmab A/SLTM Jun 2026$788.1M USD—-43.9%19.1%
CGENCompugen Ltd.LTM Mar 2026$34.86M USD+346.4%—48.0%
LEGNLegend Biotech CorporationLTM Sep 2026-$215K USD+99.9%—0.0%
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M USD-26.1%—44.8%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$88.87M USD+31.7%——
ADCTADC Therapeutics S.A.LTM Mar 2026-$136.99M USD+8.6%—173.0%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$220.54M USD+44.5%—58.2%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M USD-47.7%—386.3%
BNTXBioNTech SELTM Jun 2026-€1.69B EUR-390.8%—64.0%
Peer median (excluding GMAB) —+37.3%+59.1%48.0%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Revenue8.42B14.51B16.47B21.53B3.72B
Cost of Revenue00226M985M309.24M
Gross Profit8.42B14.51B16.25B20.54B3.41B
Gross Margin100.0%100.0%98.6%95.4%91.7%
Research & Development4.18B5.56B7.63B9.75B1.56B
Selling, General & Admin1.28B2.68B3.3B3.79B602.47M
Operating Expenses5.46B8.24B10.93B13.84B2.16B
Depreciation & Amortization248.99M362M293.62M413M71.06M
EBITDA4.18B7.35B6B9.7B1.34B
EBITDA Margin49.7%50.6%36.4%45.0%35.9%
Operating Income2.95B6.27B5.32B6.7B1.25B
Operating Margin35.1%43.2%32.3%31.1%33.6%
Interest Income197M324M939M995M138.11M
Interest Expense13M21M27M120M61.05M
Other Income / Expenses965M678M316M2.46B(46.04M)
Income Before Tax3.92B6.95B5.64B9.16B1.2B
Pre-Tax Margin46.5%47.9%34.2%42.6%32.4%
Income Tax Expense961M1.49B1.29B1.32B241.19M
Net Income2.96B5.45B4.35B7.84B963.76M
Net Margin35.1%37.6%26.4%36.4%25.9%
EPS (Basic)4.528.346.6012.141.55
EPS (Diluted)4.488.266.6012.141.54
Weighted Avg Shares653.96M653.87M659.15M646.33M621.51M
Weighted Avg Shares (Diluted)660.46M660.1M659.15M646.33M626.92M

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.